ERBB2 and breast cancer: To better elucidate other potential molecular alterations that contributes to the difference in the sensitivity to palbociclib between luminal or HER2-positive breast cancer and triple-negative breast tumors, we therefore explored the effects of palbociclib in a panel of human breast cancer cell lines representative of different breast cancer subtypes.